Sab Biotherapeutics, Inc. · NASDAQ:SABS
Sab Biotherapeutics — European Association for the Study of Diabetes 60th Annual Meeting, Innodia Symposium 2024
14 slides from Sab Biotherapeutics's conference presentation, Sep 9, 2024
Slide 1: SAB Biotherapeutics at EASD 60th Annual Meeting Innodia Symposium
SAB Biotherapeutics European Association for the Study of Diabetes 60th Annual Meeting INNODIA SYMPOSIUM Madrid, Spain September 9, 2024 © 2024 SAB BIOTHERAPEUTICS, INC. EXHIBIT 99.2
Slide 2: Protecting Pancreatic Beta Cells with Multi-target Immunotherapy: SAB-142
Protecting Pancreatic Beta Cells with Multi-target Immunotherapy: SAB-142 © 2024 SAB BIOTHERAPEUTICS, INC.
Slide 3: Forward-Looking Statements
Forward-Looking Statements The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (“SAB”) and is general background information about SAB’s activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete.
Slide 4: SAB-142 Value: Fully Human Multi-target Immunotherapy
SAB-142 Value: Fully Human Multi-target Immunotherapy SAB-142 is the first and only fully human multi-target, multi-epitope biologic to enable safe and reliable dosing over a patient’s lifetime to delay onset and/or progression of Type 1 Diabetes © 2024 SAB BIOTHERAPEUTICS, INC.
Slide 5: Multi-target capability in a single therapeutic
Multi-target capability in a single therapeutic Natural multi-epitope targeted hIgG selected and produced in vivo Ability to target multiple T1D disease pathways at once Specifically driven high-potency titers and avidity Potential for better safety & reliable re-dosing due to low risk for immunogen
Slide 6: Complex Pathophysiology of T1D Demands Multi-Target Approach
Complex Pathophysiology of T1D Demands Multi-Target Approach SAB-142 Preserves Treg Cells Identical in vitro Binding vs Thymoglobulin SAB-142 vs. Rabbit THYMO-AF488 SAB-142 CD8 T Cells - Reduction Live CD8+ cells * * * * Treg Cells – No Change Live CD4+CD25+Foxp3+ * Indicates p<0.05 compared to nega
Slide 7: SAB-142 Production is Similar to Thymoglobulin
SAB-142 Production is Similar to Thymoglobulin® © 2024 SAB BIOTHERAPEUTICS, INC. rpAbs hpAbs Thymocytes Thymocytes Rabbit Immunization Rabbit Antibody Production Plasma Collection Purification Rabbit Antibodies SAB-142 Anti-Thymocyte Globulin (Human)
Slide 8: Serum Sickness Associated with Heterologous Biologics
Serum Sickness Associated with Heterologous Biologics Pathophysiology and treatment Serum sickness is a type III hypersensitivity reaction that is induced by administration of foreign proteins Mediated by immune complex deposition, which leads to complement activation and recruitment of neutrophils
Slide 9: SAB-142 Offers Several Distinct Advantages Over Thymoglobulin
SAB-142 Offers Several Distinct Advantages Over Thymoglobulin® Majority of patients develop grade 3-4 serum sickness Safety Efficacy No serum sickness due to fully human product Lower half-life and inability to re-dose due to anti-drug antibodies No immunogenicity allows safe and reliable re-dosing
Slide 10: HUMAN Clinical Trial Study Design
HUMAN Clinical Trial STUDY DESIGN Phase 1: First in Human, Randomized, Double-Blind, Placebo-controlled, Single Ascending Dose trial in healthy volunteers with adaptation to patients with T1D SAB-142 doses: 0.03mg/kg, 0.1, 0.5, 1.5 & 2.5mg/kg ENDPOINTS Primary end point: Acute (serum sickness, CRS)
Slide 11: Established Differentiated Safety Profile of SAB-142: Proven No Serum Sickness
Established Differentiated Safety Profile of SAB-142 to Allow Safe and Reliable Dosing: Proven No Serum Sickness Study Progress Completed all planned HV cohorts Completed dosing with 2.5mg/kg of SAB-142, preliminary target dose Established differentiated safety profile to allow safe and reliable dos
Slide 12: SAFEGUARD Trial: Global Collaboration Across Key T1D Centers
SAFEGUARD Trial: Global Collaboration Across Key T1D Centers United States (FDA) United Kingdom (MHRA) Europe (EMA) Australia (TGA) SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes SAFEGUARD © 2024 SAB BIOTHERAPEUTICS, INC. Filed in US and e
Slide 13: SAFEGUARD Study Design
SAFEGUARD Study Design A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of SAB-142 for the delay of progression of Type 1 Diabetes in new/recent onset Stage 3 T1D patients © 2024 SAB BIOTHERAPEUTICS, INC.
Slide 14: Questions? Contact us
Questions? Contact us @ SAFEGUARD@sab.bio www.safeguardstudy.com www.safeguardt1dtrial.net © 2024 SAB BIOTHERAPEUTICS, INC.